RCT: Efficacy and safety of Daprodustat (oral drug) for treating anemia of chronic kidney disease in incident dialysis patients.

Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients: A Randomized Clinical Trial – JAMA Internal Medicine

Related:

RCT: In patients with chronic kidney diseases and anemia undergoing dialysis, Daprodustat (oral drug) was noninferior to darbepoetin alfa to increase hemoglobin levels and regarding cardiovascular outcomes.

RCT: In patients with chronic kidney diseases and anemia not undergoing dialysis, Daprodustat (oral drug) was noninferior to darbepoetin alfa in increasing hemoglobin levels and regarding cardiovascular outcomes.

Commentary on Twitter

In this RCT, daprodustat was noninferior to darbepoetin alfa in treating anemia of chronic kidney disease. Daprodustat represents an oral alternative treatment to a conventional erythropoiesis-stimulating agent in the incident dialysis population. https://t.co/uoYOcpSam6

— JAMA Internal Medicine (@JAMAInternalMed) April 4, 2022